After a 20% year-to-date decline, Cassava Sciences (SAVA) could see another downside in the coming months as circumstances may not be ideal for the company to develop its treatment for Alzheimer's disease. As I see no potential for a price recovery here, I am bearish on this stock. Cassava Sciences is a clinical-stage biotech company committed to developing innovative therapies for Alzheimer's disease. Its lead treatment candidate, called Simufilam, is currently in Phase 3 clinical trials after receiving a special protocol review from the U.S. Food and Drug Administration (FDA).
https://www.tipranks.com/news/article/cassava-sciences-little-chance-of-a-rebound?utm_source=advfn.com&utm_medium=referral
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Cassava Sciences Charts.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Cassava Sciences Charts.